Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Infliximab"" wg kryterium: Temat


Tytuł :
Infliximab treatment in refractory vascular Behcet's disease: A single-center experience.
Autorzy :
Kehribar DY; Ondokuz Mayis University Faculty of Medicine Körfez Mahallesi Atakum Samsun, samsun 55139 Turkey.
Ozgen M; Ondokuz Mayis Universitesi Tip Fakultesi Samsun, Turkey.
Pokaż więcej
Źródło :
Vascular [Vascular] 2020 Dec; Vol. 28 (6), pp. 829-833. Date of Electronic Publication: 2020 May 23.
Typ publikacji :
Journal Article
MeSH Terms :
Behcet Syndrome/*drug therapy
Immunosuppressive Agents/*therapeutic use
Infliximab/*therapeutic use
Adult ; Aged ; Behcet Syndrome/diagnosis ; Behcet Syndrome/immunology ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infliximab/adverse effects ; Male ; Middle Aged ; Remission Induction ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Turkey ; Young Adult
Czasopismo naukowe
Tytuł :
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.
Autorzy :
Martínez-Feito A; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain. .; Immunology Unit, La Paz University Hospital, Madrid, Spain. .
Bravo-Gallego LY; Immunology Unit, La Paz University Hospital, Madrid, Spain.; Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ) and Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
Hernández-Breijo B; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Diez J; Biostatistics Section, La Paz University Hospital, Madrid, Spain.
García-Ramirez L; Unit of Inflammatory Bowel Disease, Gastroenterology Department. Innate Immunity Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Jaquotot M; Unit of Inflammatory Bowel Disease, Gastroenterology Department. Innate Immunity Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Plasencia-Rodríguez C; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Nozal P; Immunology Unit, La Paz University Hospital, Madrid, Spain.
Mezcua A; Immunology Unit, La Paz University Hospital, Madrid, Spain.
Martín-Arranz MD; Unit of Inflammatory Bowel Disease, Gastroenterology Department. Innate Immunity Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Pascual-Salcedo D; Immuno-Rheumatology Group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 13; Vol. 10 (1), pp. 17099. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*pharmacokinetics
Biosimilar Pharmaceuticals/*pharmacokinetics
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*pharmacokinetics
Adolescent ; Adult ; Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/therapeutic use ; Biomarkers/blood ; Biosimilar Pharmaceuticals/blood ; Biosimilar Pharmaceuticals/therapeutic use ; Female ; Humans ; Inflammatory Bowel Diseases/blood ; Infliximab/blood ; Infliximab/therapeutic use ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA.
Autorzy :
Lim MH; Department of Gastroenterology, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
Aluzaite K; Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Schultz M; Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.; Gastroenterology Unit, Dunedin Public Hospital, Southern District Health Board, Dunedin, New Zealand.
Casey P; Department of Gastroenterology, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
Pokaż więcej
Źródło :
Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2020 Aug; Vol. 35 (8), pp. 1302-1306. Date of Electronic Publication: 2020 Jan 16.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Drug Dosage Calculations*
Enzyme-Linked Immunosorbent Assay*
Drug Monitoring/*methods
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*blood
Humans ; Inflammatory Bowel Diseases/blood ; Infliximab/administration & dosage ; Maintenance Chemotherapy
Czasopismo naukowe
Tytuł :
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Autorzy :
Porcari S; Clinical Division for Chronic Bowel Disorders, IBD-UNIT, A.O.U. Policlinico 'G. Martino', Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.
Viola A; Clinical Division for Chronic Bowel Disorders, IBD-UNIT, A.O.U. Policlinico 'G. Martino', Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.
Orlando A; Inflammatory Bowel Disease Unit, A.O.O.R. 'Villa Sofia-Cervello', Palermo, Italy.
Privitera AC; Inflammatory Bowel Disease Unit, A.O. 'Cannizzaro', Catania, Italy.
Ferracane C; Inflammatory Bowel Disease Unit, A.O. 'Cannizzaro', Catania, Italy.
Cappello M; Gastroenterology and Hepatology Unit, A.O.U. Policlinico 'G. Giaccone', Palermo, Italy.
Vitello A; Gastroenterology and Hepatology Unit, A.O.U. Policlinico 'G. Giaccone', Palermo, Italy.
Siringo S; Gastroenterology Unit, A.R.N.A.S. 'Garibaldi', Catania, Italy.
Inserra G; Internal Medicine Unit, A.O.U. Policlinico 'Vittorio Emanuele', University of Catania, Catania, Italy.
Magnano A; Gastroenterology Unit, A.O.U. Policlinico 'Vittorio Emanuele', Catania, Italy.
Mocciaro F; Gastroenterology and Endoscopy Unit, A.R.N.A.S. 'Civico Di Cristina Benfratelli', Palermo, Italy.
Di Mitri R; Gastroenterology and Endoscopy Unit, A.R.N.A.S. 'Civico Di Cristina Benfratelli', Palermo, Italy.
Belluardo N; Gastroenterology Unit, A.O. 'Guzzardi', Vittoria, Italy.
Fidanza O; Clinical Division for Chronic Bowel Disorders, IBD-UNIT, A.O.U. Policlinico 'G. Martino', Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.
Garufi S; Gastroenterology Unit, A.O.O.R. 'S. Elia- M. Raimondi', Caltanissetta, Italy.
Magrì G; Gastroenterology Unit, A.O. 'Santa Marta e S. Venera', Acireale, Italy.
Bertolami C; Gastroenterology Unit, A.O.O.R. 'Papardo Piemonte', Messina, Italy.
Carroccio A; Internal Medicine Unit, A.O. 'Giovanni Paolo II', Sciacca, Italy.
Macaluso FS; Inflammatory Bowel Disease Unit, A.O.O.R. 'Villa Sofia-Cervello', Palermo, Italy.
Renna S; Inflammatory Bowel Disease Unit, A.O.O.R. 'Villa Sofia-Cervello', Palermo, Italy.
Ventimiglia M; Inflammatory Bowel Disease Unit, A.O.O.R. 'Villa Sofia-Cervello', Palermo, Italy.
Alibrandi A; Department of Economics, University of Messina, Messina, Italy.
Cottone M; Inflammatory Bowel Disease Unit, A.O.O.R. 'Villa Sofia-Cervello', Palermo, Italy.
Fries W; Clinical Division for Chronic Bowel Disorders, IBD-UNIT, A.O.U. Policlinico 'G. Martino', Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy. .
Pokaż więcej
Corporate Authors :
Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Źródło :
Drugs & aging [Drugs Aging] 2020 May; Vol. 37 (5), pp. 383-392.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Adalimumab/*therapeutic use
Antibodies, Monoclonal/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*therapeutic use
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Withholding Treatment/*statistics & numerical data
Adalimumab/administration & dosage ; Adalimumab/adverse effects ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Cohort Studies ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; Humans ; Inflammatory Bowel Diseases/epidemiology ; Infliximab/administration & dosage ; Infliximab/adverse effects ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Retrospective Studies ; Treatment Failure
Czasopismo naukowe
Tytuł :
Infliximab Use in a Child With Ulcerative Colitis and Prior In Utero Exposure to Infliximab.
Autorzy :
Lim J; Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California.
Hammami MB; Department of Medicine, University of California, Riverside, Riverside, California; Division of Gastroenterology and Hepatology, Veterans Affairs Loma Linda Health Care System, Loma Linda, California.
Mahadevan U; Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California. Electronic address: .
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2020 May; Vol. 158 (6), pp. 1834-1835. Date of Electronic Publication: 2020 Jan 08.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Maternal Exposure*
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Pregnancy Complications/*drug therapy
Adolescent ; Adult ; Child ; Child, Preschool ; Colitis, Ulcerative/blood ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/immunology ; Colonoscopy ; Crohn Disease/immunology ; Drug Therapy, Combination ; Female ; Gastrointestinal Agents/immunology ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Infliximab/immunology ; Infliximab/pharmacokinetics ; Male ; Medical History Taking ; Pregnancy ; Pregnancy Complications/immunology ; Remission Induction/methods ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study.
Autorzy :
Ishida N; First Department of Medicine.
Miyazu T; First Department of Medicine.
Sugiyama T; First Department of Medicine.
Tamura S; First Department of Medicine.
Kagami T; First Department of Medicine.
Tani S; Department of Endoscopic and Photodynamic Medicine.
Yamade M; First Department of Medicine.
Iwaizumi M; Department of Laboratory Medicine.
Hamaya Y; First Department of Medicine.
Osawa S; Department of Endoscopic and Photodynamic Medicine.
Furuta T; Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Sugimoto K; First Department of Medicine.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jul 17; Vol. 99 (29), pp. e21226.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adolescent ; Adult ; Aged ; Cohort Studies ; Crohn Disease/blood ; Disease Progression ; Female ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Infliximab/pharmacokinetics ; Male ; Middle Aged ; Prospective Studies ; Remission Induction ; Young Adult
Czasopismo naukowe
Tytuł :
Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents.
Autorzy :
Hejazi ME; Internal medicine department, Tabriz University of Medical Sciences, Tabriz, Iran.
Ahmadzadeh A; Internal medicine department, Tabriz University of Medical Sciences, Tabriz, Iran. .
Khabbazi A; Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ebrahimi A; Internal medicine department, Tabriz University of Medical Sciences, Tabriz, Iran.
Farmani M; Internal medicine department, Tabriz University of Medical Sciences, Tabriz, Iran.
Hejazi Y; Internal medicine department, Tabriz University of Medical Sciences, Tabriz, Iran.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2020 Jul 02; Vol. 20 (1), pp. 464. Date of Electronic Publication: 2020 Jul 02.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Antirheumatic Agents/*therapeutic use
Infliximab/*therapeutic use
Rheumatic Diseases/*drug therapy
Tuberculin Test/*methods
Tuberculosis/*diagnosis
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Adult ; Antirheumatic Agents/pharmacology ; Chronic Disease ; Female ; Humans ; Infliximab/pharmacology ; Male ; Mass Screening/methods ; Middle Aged ; Prospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
Autorzy :
Baker JF; Corporal Michael J. Crescenz VA Medical Center and University of Pennsylvania Perelman School of Medicine, Philadelphia.
Leonard CE; University of Pennsylvania Perelman School of Medicine, Philadelphia.
Lo Re V 3rd; University of Pennsylvania Perelman School of Medicine, Philadelphia.
Weisman MH; Cedars-Sinai Medical Center, Los Angeles, California.
George MD; University of Pennsylvania Perelman School of Medicine, Philadelphia.
Kay J; University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester.
Pokaż więcej
Źródło :
Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2020 Jul; Vol. 72 (7), pp. 1067-1071. Date of Electronic Publication: 2020 May 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Academic Medical Centers*
United States Department of Veterans Affairs*
Antirheumatic Agents/*therapeutic use
Biosimilar Pharmaceuticals/*therapeutic use
Filgrastim/*therapeutic use
Hematologic Agents/*therapeutic use
Infliximab/*therapeutic use
Antirheumatic Agents/economics ; Biosimilar Pharmaceuticals/economics ; Cost Savings ; Drug Costs ; Filgrastim/economics ; Gastroenterology ; Hematologic Agents/economics ; Humans ; Infliximab/economics ; Infusions, Intravenous ; Medicare Part B ; Motivation ; Philadelphia ; Polyethylene Glycols/economics ; Polyethylene Glycols/therapeutic use ; Reimbursement Mechanisms ; Rheumatology ; United States
Czasopismo naukowe
Tytuł :
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.
Autorzy :
Kim SC; Brigham and Women's Hospital.
Sarpatwari A; Brigham and Women's Hospital.
Landon JE; Brigham and Women's Hospital.
Desai RJ; Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Pokaż więcej
Źródło :
Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2020 Jun; Vol. 72 (6), pp. 1036-1038. Date of Electronic Publication: 2020 Apr 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antirheumatic Agents/*therapeutic use
Biosimilar Pharmaceuticals/*therapeutic use
Health Care Costs/*trends
Infliximab/*therapeutic use
Patient Acceptance of Health Care/*statistics & numerical data
Rheumatic Diseases/*drug therapy
Tumor Necrosis Factor Inhibitors/*therapeutic use
Antirheumatic Agents/economics ; Biosimilar Pharmaceuticals/economics ; Humans ; Infliximab/economics ; Rheumatic Diseases/economics ; Tumor Necrosis Factor Inhibitors/economics ; United States
Czasopismo naukowe
Tytuł :
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
Autorzy :
Hupé M; Bordeaux, France.
Rivière P; Bordeaux, France.
Nancey S; Lyon, France.
Roblin X; Saint-Etienne, France.
Altwegg R; Montpellier, France.
Filippi J; Nice, France.
Fumery M; Amiens, France.
Bouguen G; Rennes, France.
Peyrin-Biroulet L; Nancy, France.
Bourreille A; Nantes, France.
Caillo L; Nîmes, France.
Simon M; Pau, France.
Goutorbe F; Bayonne, France.
Laharie D; Bordeaux, France.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 May; Vol. 51 (9), pp. 852-860. Date of Electronic Publication: 2020 Mar 22.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Adalimumab/*administration & dosage
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Infliximab/*therapeutic use
Adalimumab/adverse effects ; Adult ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Biological Factors/administration & dosage ; Biological Factors/adverse effects ; Cohort Studies ; Colitis, Ulcerative/pathology ; Comparative Effectiveness Research ; Drug Substitution ; Female ; Humans ; Infliximab/adverse effects ; Injections, Subcutaneous ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Young Adult
Czasopismo naukowe
Tytuł :
Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports.
Autorzy :
Lu J; Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
Li Y; Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
Yu N; Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
Chen F; Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
Ding Y; Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
Yi X; Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
Pokaż więcej
Źródło :
The Journal of international medical research [J Int Med Res] 2020 Mar; Vol. 48 (3), pp. 300060520912091.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Dermatologic Agents/*therapeutic use
Infliximab/*therapeutic use
Psoriasis/*drug therapy
Biomarkers ; Biopsy ; Child ; Dermatologic Agents/administration & dosage ; Dermatologic Agents/adverse effects ; Humans ; Infliximab/administration & dosage ; Infliximab/adverse effects ; Male ; Psoriasis/diagnosis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway.
Autorzy :
Mohamad HE; Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt. Electronic address: .
Asker ME; Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Keshawy MM; Department of Internal Medicine, Nephrology Division, Faculty of Medicine, Ismailia, 41522, Suez Canal University, Egypt.
Abdel Aal SM; Department of Histology& Cell Biology, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Mahmoud YK; Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt.
Pokaż więcej
Źródło :
European journal of pharmacology [Eur J Pharmacol] 2020 Apr 05; Vol. 872, pp. 172959. Date of Electronic Publication: 2020 Jan 29.
Typ publikacji :
Journal Article
MeSH Terms :
Insulin Resistance*
Infliximab/*pharmacology
Insulin/*metabolism
Kidney/*drug effects
Signal Transduction/*drug effects
Animals ; Blood Glucose/analysis ; Blood Glucose/metabolism ; Disease Models, Animal ; Glucose Tolerance Test ; Humans ; Hyperglycemia/blood ; Hyperglycemia/complications ; Hyperglycemia/drug therapy ; Hyperglycemia/metabolism ; Infliximab/therapeutic use ; Insulin Receptor Substrate Proteins/metabolism ; Kidney/metabolism ; Male ; Metformin/pharmacology ; Metformin/therapeutic use ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Rats ; Renal Insufficiency, Chronic/blood ; Renal Insufficiency, Chronic/metabolism ; Renal Insufficiency, Chronic/prevention & control ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe
Tytuł :
Lactic acidemia due to an infliximab infusion reaction.
Autorzy :
Vigh N; Department of Emergency Medicine, Good Samaritan Hospital Medical Center, West Islip, NY, United States. Electronic address: .
Levy D; Department of Emergency Medicine, Good Samaritan Hospital Medical Center, West Islip, NY, United States.
Pokaż więcej
Źródło :
The American journal of emergency medicine [Am J Emerg Med] 2020 Apr; Vol. 38 (4), pp. 850.e1-850.e3. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji :
Case Reports
MeSH Terms :
Acidosis, Lactic/*chemically induced
Antirheumatic Agents/*adverse effects
Infliximab/*adverse effects
Adult ; Antirheumatic Agents/therapeutic use ; Arthralgia/drug therapy ; Emergency Service, Hospital ; Female ; Humans ; Infliximab/therapeutic use
Raport
Tytuł :
Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
Autorzy :
Takeuchi I; Center for Pediatric Inflammatory Bowel Disease Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Kaburaki Y; Center for Pediatric Inflammatory Bowel Disease Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.; Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan.
Arai K; Center for Pediatric Inflammatory Bowel Disease Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Shimizu H; Center for Pediatric Inflammatory Bowel Disease Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.; Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hirano Y; Center for Pediatric Inflammatory Bowel Disease Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Nagata S; Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan.
Shimizu T; Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło :
Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2020 Apr; Vol. 35 (4), pp. 593-600. Date of Electronic Publication: 2019 Nov 14.
Typ publikacji :
Journal Article
MeSH Terms :
Gastrointestinal Agents/*therapeutic use
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*administration & dosage
Adolescent ; Adult ; Age Factors ; Anus Diseases/complications ; Anus Diseases/drug therapy ; Child ; Child, Preschool ; Colitis, Ulcerative/complications ; Colitis, Ulcerative/drug therapy ; Female ; Humans ; Infant ; Infliximab/therapeutic use ; Japan ; Male ; Middle Aged ; Retrospective Studies ; Tertiary Care Centers ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels.
Autorzy :
Neveu B; OPTILAB Montréal-CHUM, Hôpital Maisonneuve-Rosemont, 5415 Boulevard de l'Assomption, Montréal, Québec H1T 2M4, Canada.
Kunst A; Alberta Public Laboratories, University of Alberta Hospital, 8440 112 Street NW, Edmonton, Alberta T6G 2B7, Canada. Electronic address: .
Prosser C; Alberta Public Laboratories, University of Alberta Hospital, 8440 112 Street NW, Edmonton, Alberta T6G 2B7, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, 4B1.19 Walter Mackenzie Centre, 8440 112 Street NW, Edmonton, Alberta T6G 2B7, Canada. Electronic address: .
Robitaille R; OPTILAB Montréal-CHUM, Hôpital Maisonneuve-Rosemont, 5415 Boulevard de l'Assomption, Montréal, Québec H1T 2M4, Canada. Electronic address: .
Pokaż więcej
Źródło :
Clinical biochemistry [Clin Biochem] 2020 Apr; Vol. 78, pp. 58-62. Date of Electronic Publication: 2020 Jan 23.
Typ publikacji :
Journal Article
MeSH Terms :
Biosimilar Pharmaceuticals/*blood
Enzyme-Linked Immunosorbent Assay/*methods
Infliximab/*blood
Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/immunology ; Drug Monitoring ; Humans ; Infliximab/immunology
Czasopismo naukowe
Tytuł :
An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease.
Autorzy :
Patel RN; The Whittington Hospital NHS Trust, London, UK.
Nigam GB; The Pennine Acute Hospitals NHS Trust, Manchester, UK.
Jatale RG; Department of Bio-Statistics, P D Hinduja Hospital, Mumbai, 400 016, India.
Desai D; P D Hinduja Hospital, Mumbai, 400 016, India.
Makharia G; The All India Institute of Medical Sciences, New Delhi, 110 029, India.
Ahuja V; The All India Institute of Medical Sciences, New Delhi, 110 029, India.
Limdi JK; The Pennine Acute Hospitals NHS Trust, Manchester Academic Health Sciences, University of Manchester, Manchester, UK. .
Pokaż więcej
Źródło :
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology [Indian J Gastroenterol] 2020 Apr; Vol. 39 (2), pp. 176-185. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Monitoring*/statistics & numerical data
Surveys and Questionnaires*
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*therapeutic use
Procedures and Techniques Utilization/*statistics & numerical data
Tumor Necrosis Factor Inhibitors/*therapeutic use
Adult ; Aged ; Cost-Benefit Analysis ; Female ; Humans ; India/epidemiology ; Inflammatory Bowel Diseases/economics ; Infliximab/economics ; Male ; Middle Aged ; Time Factors ; Tumor Necrosis Factor Inhibitors/economics
Czasopismo naukowe
Tytuł :
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
Autorzy :
Genovese MC; Division of Immunology and Rheumatology, Stanford University, 1000 Welch RD #203, Palo Alto, CA, USA. .
Sanchez-Burson J; Hospital Infanta Luisa, Calle San Jacinto 87, Sevilla, Spain.
Oh M; Biosimilars, Amgen, One Amgen Center Dr., Thousand Oaks, CA, USA.
Balazs E; Csongrád Megyei dr. Bugyi István Kórház Mozgásszervi Rehabilitációs, Sima Ferenc u. 44-58, Csongrad, Hungary.
Neal J; Bluegrass Community Research, 330 Waller Avenue, Lexington, KY, USA.
Everding A; Hamburger Rheuma Forschungszentrum II, Hamburg, Germany.
Hala T; CCR Czech a.s., Trida miru 2800, 53002, Pardubice, Czech Republic.
Wojciechowski R; Department of Rheumatology and Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, Poland.
Fanjiang G; Biosimilars, Amgen, One Amgen Center Dr., Thousand Oaks, CA, USA.
Cohen S; Metroplex Clinical Research, 8144 Walnut Hill Lane, Dallas, TX, USA.
Pokaż więcej
Źródło :
Arthritis research & therapy [Arthritis Res Ther] 2020 Mar 26; Vol. 22 (1), pp. 60. Date of Electronic Publication: 2020 Mar 26.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Arthritis, Rheumatoid/*drug therapy
Biosimilar Pharmaceuticals/*therapeutic use
Infliximab/*therapeutic use
Adult ; Aged ; Antirheumatic Agents/pharmacokinetics ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/pathology ; Biosimilar Pharmaceuticals/pharmacokinetics ; C-Reactive Protein/metabolism ; Double-Blind Method ; Female ; Humans ; Infliximab/pharmacokinetics ; Male ; Middle Aged ; Therapeutic Equivalency ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study.
Autorzy :
Borren NZ; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Tan W; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Colizzo FP; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Luther J; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Garber JJ; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Khalili H; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
van Der Woude CJ; Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Ananthakrishnan AN; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Mar 13; Vol. 14 (3), pp. 309-315.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/adverse effects
Colitis, Ulcerative*/diagnosis
Colitis, Ulcerative*/drug therapy
Colitis, Ulcerative*/physiopathology
Crohn Disease*/diagnosis
Crohn Disease*/drug therapy
Crohn Disease*/physiopathology
Fatigue*/diagnosis
Fatigue*/etiology
Infliximab*/administration & dosage
Infliximab*/adverse effects
Ustekinumab*/administration & dosage
Ustekinumab*/adverse effects
Biological Therapy/*adverse effects
Adult ; Biological Therapy/methods ; Cohort Studies ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Male ; Netherlands/epidemiology ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
Autorzy :
Kim HA; Ajou University School of Medicine, Suwon, Republic of Korea.
Lee E; Ajou University School of Medicine, Suwon, Republic of Korea.
Lee SK; Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Park YB; Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Lee YN; Celltrion Healthcare Co. Ltd, Incheon, Republic of Korea.
Kang HJ; Celltrion Healthcare Co. Ltd, Incheon, Republic of Korea.
Shin K; Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea. .
Pokaż więcej
Źródło :
Clinical and experimental rheumatology [Clin Exp Rheumatol] 2020 Mar-Apr; Vol. 38 (2), pp. 267-274. Date of Electronic Publication: 2019 Jul 19.
Typ publikacji :
Journal Article
MeSH Terms :
Antirheumatic Agents*/adverse effects
Antirheumatic Agents*/therapeutic use
Biosimilar Pharmaceuticals*/adverse effects
Biosimilar Pharmaceuticals*/therapeutic use
Infliximab*/adverse effects
Infliximab*/therapeutic use
Spondylitis, Ankylosing*/drug therapy
Spondylitis, Ankylosing*/immunology
Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Humans ; Registries ; Republic of Korea ; Rheumatology ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Reactivation of Plasmodium infection during a treatment with infliximab: A case report.
Autorzy :
Haeseleer C; Department of Hematology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium. Electronic address: .
Martiny D; Department of Microbiology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium; Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.
Van Laethem Y; Department of Infectious Diseases, Centre Hospitalier Universitaire Saint- Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Cantinieaux B; Department of Hematology, Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.
Martin C; Department of Infectious Diseases, Centre Hospitalier Universitaire Saint- Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Pokaż więcej
Źródło :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2020 Feb; Vol. 91, pp. 101-103. Date of Electronic Publication: 2019 Nov 20.
Typ publikacji :
Case Reports
MeSH Terms :
Infliximab/*adverse effects
Malaria, Falciparum/*etiology
Adult ; Humans ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/drug therapy ; Infliximab/therapeutic use ; Male ; Plasmodium falciparum ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies